Ganzheng

Ganzheng Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of novel therapies for chronic liver diseases. The company's primary focus is on achieving a functional cure for chronic Hepatitis B (CHB) through the development of highly potent small molecule inhibitors. Its lead candidate, GZ-01, is a Hepatitis B virus (HBV) capsid assembly modulator (CAM) currently undergoing clinical evaluation in Phase 1 trials. Ganzheng's research strategy emphasizes targeting multiple stages of the HBV life cycle to disrupt viral replication and restore the host immune response. Supported by leading venture capital firms like Qiming Venture Partners, the company aims to address the significant global health burden of liver disease.